Servier India, a subsidiary of the French pharmaceutical company Servier Group, has launched a nationwide biomarker testing initiative in collaboration with MedGenome and Strand Life Sciences to improve access to advanced molecular diagnostics for two cancer types — Acute Myeloid Leukaemia (AML) and Cholangiocarcinoma (CCA). The initiative aims to make precision diagnostics more affordable, accessible, and integrated into routine oncology practice across India.
The program introduces a customized biomarker testing panel for AML and CCA, available across both private and government healthcare sectors at subsidized rates. In a significant step toward equitable healthcare access, IDH1 and IDH2 mutation testing for patients with AML and CCA will be provided free of cost in the government sector. This initiative focuses on bridging a critical gap in India’s molecular testing landscape, which remains concentrated in urban centers and accessible to only a limited patient population.
For private sector facilities, the cost of molecular testing will be reduced by 60% to 75%, significantly lowering financial barriers. Typically, AML testing costs between ₹20,000 and ₹50,000, while CCA testing ranges from ₹70,000 to ₹3,00,000. By reducing costs and expanding coverage, the initiative aims to ensure that patients across the country receive timely and accurate molecular diagnoses that can directly influence treatment outcomes.
Servier India emphasized that early molecular testing in cancers like AML and CCA can improve survival outcomes by enabling timely, personalized treatment strategies. The company highlighted the importance of precision diagnosis as the foundation of precision oncology, noting that identifying genetic mutations such as IDH1 and IDH2 plays a pivotal role in guiding therapy decisions.
The initiative also aims to strengthen collaboration among laboratories, clinicians, and patient care networks, ensuring smoother coordination across the diagnostic and treatment pathways.
Launched under the ‘Servier Care’ patient support program, the initiative provides comprehensive support to eligible patients, including financial aid, subsidized diagnostics, and free drug support, where legally permissible. This approach reflects Servier India’s commitment to building sustainable access to precision oncology and improving cancer care outcomes across India.
Also Read